Chemours Appoints New Directors, Adjusts Executive Compensation

Ticker: CC · Form: 8-K · Filed: Jun 13, 2024 · CIK: 1627223

Chemours Co 8-K Filing Summary
FieldDetail
CompanyChemours Co (CC)
Form Type8-K
Filed DateJun 13, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: board-changes, executive-compensation

TL;DR

Chemours adds 2 directors to the board and revises exec pay.

AI Summary

On June 12, 2024, The Chemours Company announced changes to its Board of Directors. Mark P. Vergnano and Dawn R. Riley have been appointed to the Board, effective immediately. Additionally, the company has entered into a new compensatory arrangement for its named executive officers.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board changes and executive compensation adjustments can introduce uncertainty regarding future strategic direction and management stability.

Key Players & Entities

  • The Chemours Company (company) — Registrant
  • Mark P. Vergnano (person) — Newly appointed Director
  • Dawn R. Riley (person) — Newly appointed Director
  • June 12, 2024 (date) — Effective date of board changes

FAQ

Who are the new members appointed to The Chemours Company's Board of Directors?

Mark P. Vergnano and Dawn R. Riley have been appointed to the Board of Directors.

When were the new directors appointed?

The new directors were appointed effective June 12, 2024.

What other significant event is reported in this 8-K filing?

The filing also reports on compensatory arrangements for certain officers.

What is the principal executive office address for The Chemours Company?

The principal executive offices are located at 1007 Market Street, Wilmington, Delaware 19801.

What is the IRS Employer Identification Number for The Chemours Company?

The IRS Employer Identification Number is 46-4845564.

Filing Stats: 655 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-13 16:36:44

Key Financial Figures

  • $0.01 — nge on Which Registered Common Stock ($0.01 par value) CC New York Stock Exchan

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated as of June 13, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CHEMOURS COMPANY By: /s/ Matthew S. Abbott Matthew S. Abbott Interim Chief Financial Officer Date: June 13, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.